Cognito Therapeutics Analysis: $423M Raised
What is Cognito Therapeutics?
Cognito Therapeutics develops non-invasive neuromodulation therapy to treat Alzheimer’s disease by evoking gamma wave activity through visual and auditory stimulation. The therapy aims to preserve brain volume, cognition, and daily function in patients. It received FDA Breakthrough Device Designation for Alzheimer’s and showed significant slowing of disease progression in a feasibility study.
Location
Cambridge, United States
Employees
51-200
Founded
2016
Funding Status
Series C
Product Features & Capabilities
- Neuromodulation therapy evoking gamma wave activity via visual and auditory stimulation
- Non-invasive home-based treatment for one hour daily
- FDA Breakthrough Device Designation for Alzheimer’s disease
Use Cases
Preserve brain volume in Alzheimer’s patients through daily home treatment; Slow cognitive and functional decline in early-stage Alzheimer’s; Maintain daily function in patients with mild cognitive impairment; Treat patients with abnormal gamma wave activity; Expand to other neurodegenerative diseases
Other Considerations
Received FDA Breakthrough Device Designation for Alzheimer’s; Showed significant slowing of disease progression in OVERTURE feasibility study; Expanding to other neurodegenerative diseases; Published at AAIC25; Featured in Bloomberg and Nasdaq interviews; Active clinical study pipeline with HOPE study ongoing
See something that needs updating? Suggest edits to this profile.